Vestmark Advisory Solutions Inc. Sells 7,795 Shares of Genmab A/S (NASDAQ:GMAB)

Vestmark Advisory Solutions Inc. reduced its position in shares of Genmab A/S (NASDAQ:GMAB) by 27.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 20,184 shares of the company’s stock after selling 7,795 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Genmab A/S were worth $421,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Lindbrook Capital LLC increased its stake in Genmab A/S by 105.4% during the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after purchasing an additional 950 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after acquiring an additional 1,051 shares during the last quarter. Cromwell Holdings LLC boosted its holdings in shares of Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after acquiring an additional 2,496 shares during the last quarter. R Squared Ltd purchased a new stake in shares of Genmab A/S during the 4th quarter valued at about $93,000. Finally, Blue Trust Inc. boosted its holdings in shares of Genmab A/S by 33.4% during the 4th quarter. Blue Trust Inc. now owns 5,757 shares of the company’s stock valued at $120,000 after acquiring an additional 1,442 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Trading Up 1.8 %

GMAB opened at $24.14 on Friday. The company has a market cap of $15.98 billion, a price-to-earnings ratio of 13.87, a PEG ratio of 2.65 and a beta of 0.98. The company’s 50 day moving average is $21.28 and its 200 day moving average is $22.66. Genmab A/S has a 12-month low of $18.64 and a 12-month high of $31.88.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, analysts predict that Genmab A/S will post 1.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on GMAB shares. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. BNP Paribas raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a report on Thursday, February 13th. Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a report on Thursday, January 23rd. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.17.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.